AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.

AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing ...

Sino and AstraZeneca sign licence agreement for TQC3721

Sino Biopharmaceutical will receive an upfront payment of $200m from AstraZeneca. The group is also eligible for further ...

US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight

A U.S. appeals court on Thursday upheld a ruling for AstraZeneca against allegations that its ​blockbuster lung-cancer drug Tagrisso infringed patents owned by ‌Pfizer subsidiary Wyeth.

AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal

Sino Biopharmaceutical will receive $200 million upfront from AstraZeneca, and will be eligible for milestone payments.
BioPharma Dive

AstraZeneca, GSK intensify China ties with Sino Biopharm deals

The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions ...

UK stocks decline as AstraZeneca tumbles after trial setback

The article flags higher gold prices plus a weaker US dollar and safe-haven demand from Middle East tensions—conditions that ...

AstraZeneca secures ex-China license for Sino Biopharmaceutical's experimental COPD drug

Hong Kong-listed Sino Biopharmaceutical said on Wednesday it ​has granted AstraZeneca the ‌rights to develop a drug designed ...

Investors reeling from Middle East conflict face fresh setback over AstraZeneca slump

Investors already grappling with renewed Middle East tensions faced fresh pressure on Thursday after heavyweight pharma firm ...